Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, presented promising outcomes from the ReSPECT-LM clinical study at the SNO/ASCO CNS Cancer Conference. The study assesses rhenium (186Re) obisbemeda’s effectiveness in treating leptomeningeal metastases (LM), it said. Rhenium (186Re)...